05 February 2024
05 February 2024
Lumosa says LT3001 should be effective if administrated within 24 hours of symptom onset, much longer than the current 4.5 hour window.
J&J MedTech’s Varipulse Platform demonstrated 12-month freedom from atrial arrhythmia recurrence in approximately 80% of the patients in inspIRE and admIRE trials.
The trial of the siRNA therapeutic SRSD107 was initiated in Australia.
Acepodia is preparing to launch the trial soon, with the first patient expected to be treated in the second half of 2024.
The Japanese trial was specifically designed to support regional registration efforts.
The primary goal of the trial is to assess the safety and tolerability of mRNA-4359.
The Clinical Trials Arena team also evaluates assets in dermatology and neurology.
Bio-Thera momentarily shifts its attention away from biosimilars as it doses the first patient with BAT6026 in Phase Ib/IIa atopic dermatitis trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
